Detailed Molecular Interactions of Favipiravir with SARS-CoV-2, SARS-CoV, MERS-CoV, and Influenza Virus Polymerases In Silico

Favipiravir was initially developed as an antiviral drug against influenza and is currently used in clinical trials against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection (COVID-19). This agent is presumably involved in RNA chain termination during influenza virus replication...

Descripción completa

Detalles Bibliográficos
Autores principales: Sada, Mitsuru, Saraya, Takeshi, Ishii, Haruyuki, Okayama, Kaori, Hayashi, Yuriko, Tsugawa, Takeshi, Nishina, Atsuyoshi, Murakami, Koichi, Kuroda, Makoto, Ryo, Akihide, Kimura, Hirokazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7589801/
https://www.ncbi.nlm.nih.gov/pubmed/33092045
http://dx.doi.org/10.3390/microorganisms8101610

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7589801/
https://www.ncbi.nlm.nih.gov/pubmed/33092045
http://dx.doi.org/10.3390/microorganisms8101610

Ejemplares similares